Business
Announcement on Subsidiary Obtaining the Registration Approval Letter for Drug Production Site Transfer of Lafamulin Injection from FDA of the United States
Announcement on Subsidiary Obtaining the Registration Approval Letter for Drug Production Site Transfer of Lafamulin Injection from FDA of the United States
About this update from Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A
Announcement on Subsidiary Obtaining the Registration Approval Letter for Drug Production Site Transfer of Lafamulin Injection from FDA of the United States The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment